

6 December 2023

Our Ref: RFI 54393

Dear

**Freedom of Information Act 2000
Information in Relation to Cancer Treatments**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 27 October 2023. Please accept my apologies for the delay in responding to your request, thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Unscheduled Care, Medicine & Cancer Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Caroline Degans
Information Governance Officer

Q1. Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases?

A1. Please see Table 1 for the number of patients treated with a combination of Dabrafenib & Trametinib for the following diseases.

Table 1

Diseases	Number of Patients Treated
Metastatic Melanoma	Nil
Adjuvant Melanoma	Nil
BRAF mutated Lung Cancer	Nil

Q2). Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases?

A2. Please see Table 2 for the number of patients treated with a combination of Encorafenib (Braftovi) & Binimetnib (Mektovi) for the following diseases.

Table 2

Diseases	Number of Patients Treated
Metastatic Melanoma	Nil
Colorectal Cancer	Nil
Any other indications	Nil